| Code | CSB-RA007690MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to eurestobart, designed to specifically target ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1), also known as CD39. ENTPD1 is a cell surface enzyme that catalyzes the hydrolysis of extracellular ATP and ADP to AMP, playing a critical role in purinergic signaling and immune regulation. By converting pro-inflammatory ATP to adenosine precursors, ENTPD1 modulates immune responses and maintains immunological homeostasis. This enzyme is highly expressed on regulatory T cells, endothelial cells, and various tumor cells, where it contributes to immunosuppressive tumor microenvironments and has been implicated in cancer immune evasion, inflammatory disorders, and transplant rejection.
Eurestobart represents a therapeutic antibody under investigation for oncology applications, particularly targeting the immunosuppressive mechanisms mediated by ENTPD1 in the tumor microenvironment. This biosimilar provides researchers with a valuable tool for investigating ENTPD1-mediated immune regulation, studying purinergic signaling pathways, and exploring novel immunotherapeutic strategies in cancer and autoimmune disease models.
There are currently no reviews for this product.